267 related articles for article (PubMed ID: 30784212)
21. MicroRNA-191 acts as a tumor promoter by modulating the TET1-p53 pathway in intrahepatic cholangiocarcinoma.
Li H; Zhou ZQ; Yang ZR; Tong DN; Guan J; Shi BJ; Nie J; Ding XT; Li B; Zhou GW; Zhang ZY
Hepatology; 2017 Jul; 66(1):136-151. PubMed ID: 28194813
[TBL] [Abstract][Full Text] [Related]
22. Enhanced gemcitabine cytotoxicity with knockdown of multidrug resistance protein genes in human cholangiocarcinoma cell lines.
Yang J; Sontag D; Gong Y; Minuk GY
J Gastroenterol Hepatol; 2021 Apr; 36(4):1103-1109. PubMed ID: 33002234
[TBL] [Abstract][Full Text] [Related]
23. Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy.
Sasaki H; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
Br J Cancer; 2014 Sep; 111(7):1275-84. PubMed ID: 25032731
[TBL] [Abstract][Full Text] [Related]
24. GDC-0980 (apitolisib) treatment with gemcitabine and/or cisplatin synergistically reduces cholangiocarcinoma cell growth by suppressing the PI3K/Akt/mTOR pathway.
Jang DK; Lee YG; Chan Chae Y; Lee JK; Paik WH; Lee SH; Kim YT; Ryu JK
Biochem Biophys Res Commun; 2020 Sep; 529(4):1242-1248. PubMed ID: 32819590
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of Wnt/β-catenin signaling downregulates P-glycoprotein and reverses multi-drug resistance of cholangiocarcinoma.
Shen DY; Zhang W; Zeng X; Liu CQ
Cancer Sci; 2013 Oct; 104(10):1303-8. PubMed ID: 23822562
[TBL] [Abstract][Full Text] [Related]
26. Upregulation of retinoic acid receptor-β reverses drug resistance in cholangiocarcinoma cells by enhancing susceptibility to apoptosis.
Ren HY; Chen B; Huang GL; Liu Y; Shen DY
Mol Med Rep; 2016 Oct; 14(4):3602-8. PubMed ID: 27599527
[TBL] [Abstract][Full Text] [Related]
27. [The mechanism of resistance to 2', 2'-difluorodeoxycytidine (gemcitabine) in a pancreatic cancer cell line].
Yao J; Feng FY; Lin C; Zhang XY; Fu M; Liang X; Yang Y
Zhonghua Zhong Liu Za Zhi; 2005 Dec; 27(12):721-6. PubMed ID: 16483481
[TBL] [Abstract][Full Text] [Related]
28. Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma.
Sato J; Kimura T; Saito T; Anazawa T; Kenjo A; Sato Y; Tsuchiya T; Gotoh M
J Hepatobiliary Pancreat Sci; 2011 Sep; 18(5):700-11. PubMed ID: 21451941
[TBL] [Abstract][Full Text] [Related]
29. Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation.
Pan YR; Wu CE; Jung SM; Huang SC; Lin SH; Chou WC; Chang YC; Chen MH; Hung TH; Yu AL; Huang WK; Yeh CN
Int J Biol Sci; 2023; 19(9):2772-2786. PubMed ID: 37324940
[TBL] [Abstract][Full Text] [Related]
30. Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.
Nakajima Y; Takagi H; Kakizaki S; Horiguchi N; Sato K; Sunaga N; Mori M
Anticancer Res; 2012 Dec; 32(12):5251-62. PubMed ID: 23225424
[TBL] [Abstract][Full Text] [Related]
31. miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.
Okamoto K; Miyoshi K; Murawaki Y
PLoS One; 2013; 8(10):e77623. PubMed ID: 24147037
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of NF-κB Activity Enhances Sensitivity to Anticancer Drugs in Cholangiocarcinoma Cells.
Seubwai W; Vaeteewoottacharn K; Kraiklang R; Umezawa K; Okada S; Wongkham S
Oncol Res; 2016 Jan; 23(1-2):21-8. PubMed ID: 26802647
[TBL] [Abstract][Full Text] [Related]
33. Two Recombinant Bacteriocins, Rhamnosin and Lysostaphin, Show Synergistic Anticancer Activity Against Gemcitabine-Resistant Cholangiocarcinoma Cell Lines.
Kerdkumthong K; Chanket W; Runsaeng P; Nanarong S; Songsurin K; Tantimetta P; Angsuthanasombat C; Aroonkesorn A; Obchoei S
Probiotics Antimicrob Proteins; 2024 Jun; 16(3):713-725. PubMed ID: 37294416
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of Tumor Growth against Chemoresistant Cholangiocarcinoma by a Proapoptotic Peptide Targeting Interleukin-4 Receptor.
Permpoon U; Khan F; Vadevoo SMP; Gurung S; Gunassekaran GR; Kim MJ; Kim SH; Thuwajit P; Lee B
Mol Pharm; 2020 Nov; 17(11):4077-4088. PubMed ID: 32881535
[TBL] [Abstract][Full Text] [Related]
35. Oncogenic activity of retinoic acid receptor γ is exhibited through activation of the Akt/NF-κB and Wnt/β-catenin pathways in cholangiocarcinoma.
Huang GL; Luo Q; Rui G; Zhang W; Zhang QY; Chen QX; Shen DY
Mol Cell Biol; 2013 Sep; 33(17):3416-25. PubMed ID: 23798555
[TBL] [Abstract][Full Text] [Related]
36. Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma.
Borbath I; Verbrugghe L; Lai R; Gigot JF; Humblet Y; Piessevaux H; Sempoux C
Eur J Cancer; 2012 May; 48(7):990-6. PubMed ID: 22137164
[TBL] [Abstract][Full Text] [Related]
37. [Mechanisms of the drug resistance of a 2', 2-difluorodeoxycytide (gemcitabine)-resistant variant of the human lung adenocarcinoma cell line].
Dong M; Feng FY; Lin C; Zhang XY; Fu M; Liang X; Zha YY; Lu HY; Wu M
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):323-8. PubMed ID: 15059518
[TBL] [Abstract][Full Text] [Related]
38. Anoikis-resistant cholangiocarcinoma cells display aggressive characteristics and increase STAT3 activation.
Huyen NT; Prachayasittikul V; Chan-On W
J Hepatobiliary Pancreat Sci; 2016 Jul; 23(7):397-405. PubMed ID: 27107220
[TBL] [Abstract][Full Text] [Related]
39. Cytotoxicity, toxicity, and anticancer activity of Zingiber officinale Roscoe against cholangiocarcinoma.
Plengsuriyakarn T; Viyanant V; Eursitthichai V; Tesana S; Chaijaroenkul W; Itharat A; Na-Bangchang K
Asian Pac J Cancer Prev; 2012; 13(9):4597-606. PubMed ID: 23167387
[TBL] [Abstract][Full Text] [Related]
40. Serine/threonine protein phosphatase 5 is a potential therapeutic target in cholangiocarcinoma.
Hu MH; Huang TT; Chao TI; Chen LJ; Chen YL; Tsai MH; Liu CY; Kao JH; Chen KF
Liver Int; 2018 Dec; 38(12):2248-2259. PubMed ID: 29797403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
